Drug intelligence / Profile preview

LU AF20513 + booster vaccine

Development stage
Unknown
Lead developer
Lundbeck
Modality
Peptides, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**LU AF20513 + booster vaccine** is a combination immunotherapy regimen intended to treat **Alzheimer’s disease**. LU AF20513 is an active immunization vaccine composed of a synthetic peptide containing repeats of the first 12 amino acids of **amyloid β (Aβ)** interspersed with helper T-cell (Th) epitopes (P2 and P30) derived from tetanus toxoid. The **booster vaccine** (administered prior to the main vaccine) is intended to activate preexisting memory T cells from previous tetanus vaccinations, leading to improved T helper cell responses, greater B cell stimulation, and increased antibody production against monomeric Aβ. The approach aims to clear amyloid plaques while avoiding autoimmune T-cell responses and is specifically optimized for older adults with diminished immunocompetence. Preclinical studies showed the vaccine induces high anti-Aβ antibody titers, reduces amyloid pathology, and is neuroprotective.

Other names
LU AF20513
02

Targets

Aβ (Amyloid-beta peptides and aggregates)CD4+ T-lymphocyte recognizing tetanus toxin epitopes P30 and P2 (TT-specific CD4+ T cell)

Beyond the preview

Go deeper on LU AF20513 + booster vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LU AF20513 + booster vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call